NovaBridge reports H1 2026 results, targets year-end Phase 3 start for givastomig

NovaBridge Biosciences reported financial results for the six months ended June 30, 2026, on August 20, 2026, alongside a pipeline update. As of June 30, 2026, the company had cash, cash equivalents, short-term investments, and equity investment at fair value totaling $215.9 million.¹ The company said this position is sufficient to fund its portfolio through several anticipated milestones, including an interim data readout from givastomig's planned Phase 3 study in 2028.¹

For givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, the company reported in January 2026 positive Phase 1b dose expansion data in first-line gastric cancer, showing a 77% overall response rate at 8 mg/kg and 73% at 12 mg/kg among 52 evaluable patients, with 16.9-month median progression-free survival at 8 mg/kg among 27 evaluable patients, and favorable tolerability without dose-dependent toxicity.¹ In February 2026, the company began a global, randomized Phase 2 study combining givastomig with immunochemotherapy in HER2-negative first-line metastatic gastric cancer.¹ In June 2026, the FDA granted givastomig Fast Track Designation for previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinoma in combination with nivolumab and chemotherapy.¹ NovaBridge said it expects to begin a Phase 3 registrational trial, potentially under an Accelerated Approval Pathway, by year-end 2026.¹

For VIS-101, an ophthalmology candidate advanced through majority-owned subsidiary Visara, the company completed initial safety and dose-escalation studies plus a randomized Phase 2a trial in China, and plans to move into a randomized, controlled Phase 2b dose-finding study in the second half of 2026, with a global Phase 3 program expected to start in 2027.¹

Financially, R&D expenses rose to $14.3 million from $4.1 million year over year, and net loss widened to $37.9 million, or $0.14 per share, from $8.7 million, or $0.05 per share, a year earlier.¹